12Jan 2019

THE VALUE OF HBSAG MONITARIZATION IN CHRONIC HEPATITIS B PATIENTS TREATED WITH ORAL ANTIVIRAL THERAPY.

  • Department of Internal Medicine, BEU,Turkey.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background:Monitarization of serum HBsAg levels during treatment of chronic hepatitis B (CHB) with pegylated interferon was popular. However, the value of HBsAg kinetics under the treatment of CHB with oral antiviral agents is not well-known. In this study we aimed to evaluate the levels of HBsAg and HBV DNA during the treatment with oral antivirals in CHB patients. Material and Method: A total of consecutive 50 CHB patients (mean age: 42.62?12.74 years and male/female: 31/19) were enrolled in this study. The serum HBsAg and HBV DNA levels at 0, 3rd and 6th month follow up in CHB patients iniated on oral antiviral therapy (lamivudine 100 mg daily, telbuvidine 600 mg daily, entecavire 0.5 or 1.0 mg daily and tenofovire 300 mg daily) were evaluated. Histologic activity index and fibrosis score were determined by Modified Knodall Classification (Ishak) in assessment of CHB biopsy specimens. Univariate and multivariate statistical methods were used by using SPSS packet programme. Results: The patients were grouped according to antiviral agents used. There was no statistically significant difference between the groups regarding age and gender (p=0.520 and p=0.816, respectively). The initial qHBSAg (log10 IU/mL) and HBV DNA (log10 IU/mL) levels were higher in HBeAg positive patients (p=0.002 and p<0.001 respectively). There was a positive correlation between the basal HBV DNA and HBsAg levels among CHB patients (r=0,398; p=0,004). At 6- month follow up, the serum HBsAg decline was significantly higher in patients treated with tenofovire (85%) and entecavire (82%) compared to those treated with telbuvidine (35%) and lamivudine (26%) (p<0.05). Conclusion: The value of the HBsAgmonitarization in CHB patients treated with antiviral therapy has not been clarified yet.

  1. The EASL Jury. EASL international consensus conference on hepatitis B. Journal of Hepatology 2009; 50: 227?42.
  2. Fattovich G, Bartolotti F, Donato F. Natural history of chronic hepatitis B Special emphasis on disease progression and prognostic factors. Journal of Hepatology 2008; 48: 335-52.
  3. Lok AS, McMahon BJ. Corrections to AASLD guidelines on chronic hepatitis B. Hepatology 2009; 50: 661-62.
  4. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582?92.
  5. Dienstag JL. Hepatitis B Vir?s İnfection. N EngJ Med 2008; 359: 1486-1500.
  6. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
  7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 2006; 45: 529-38.
  8. European guideline for the management of hepatitis B and C virus infections. International Journal of STD & AIDS 2010; 21: 669?67.
  9. EASL international consensus conferance on hepatitis B. J. Hepatology 2003; 39: 3-25.
  10. SavaşC.Kronik B HepatitiTedavisindekombinasyontedavisi. Viral HepatitKitabı 2009
  11. Chung HT. Detection of HBV DNA in serum using a PCR-based assay. Methods Mol Med. 2004;95:15-20.
  12. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg negative chronic hepatitis B. Hepatology. 2009;49: 1141?1150.
  13. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49:115?117.
  14. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan;63(1):261-83. doi: 10.1002/hep.28156. Epub 2015 Nov 13.
  15. Ishak KG, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
  16. Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?Hepatology 2004; 40(4): 790-2.
  17. Zoulim F, Carosi G, Greenbloom S, Mazur W, Nguyen T, Jeffers L, Brunetto M, Yu S, Llamoso C. Quantification of HBsAg in nucleos(t)ide-na?ve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol. 2015 Jan;62(1):56-63. doi: 10.1016/j.jhep.2014.08.031. Epub 2014 Aug 28.
  18. Brunetto MR. A new role for an old marker, HBsAg. J Hepatol 2010;52: 475?477.
  19. Chevaliez S, H?zode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely. J Hepatol. 2013 Apr;58(4):676-83. doi: 10.1016/j.jhep.2012.11.039. Epub 2012 Dec 3.
  20. Seto WK, Lam YF, Fung J, Wong DK, Huang FY, Hung IF, Lai CL, Yuen MF. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavirtreatment. J GastroenterolHepatol. 2014 May;29(5):1028-34. doi: 10.1111/jgh.12476.
  21. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011;204:415?418.
  22. heathcote, p.Marcellin, Three-Year Efficacy and Safety of TenofovirDisoproxilFumarate Treatment for Chronic Hepatitis B. gastroenterology Vol. 140, No. 1
  23. G. Gish,T.-T. Chang, C.-L. Lai, Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naı?veHBeAg-positive patients with chronic hepatitis B. Journal of Viral Hepatitis, 2010, 17, 16?22.
  24. Roeland Zoutendijk, Bettina E. Hansen, Anneke J. van Vuuren, Serum HBsAg Decline During Longterm Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss. JID 2011:204 .
  25. Fabien Zoulim, GiampieroCarosi , Susan Greenbloom , Quantification of HBsAg in nucleos(t)ide-na?ve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. Journal of Hepatology 2015 vol. 62 j 56?63
  26. Maryam Keshvari 1,2,3; SeyedMoayedAlavian 2,3; HeidarSharafi 2,3, Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients. Jundishapur J Microbiol. 2015 March; 8(3): e21444.
  27. Jie Shao, Lai Wei, Hao Wang, Yan Sun, Lan-Fang Zhang, Jing Li, Jian-Qiang Dong. Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B. World J Gastroenterol 2007 April 14; 13(14): 2104-2107.
  28. ShahinulAlam, Nooruddin Ahmad, Golam Mustafa, KhorshedAlam, Mobin Khan. Characteristics of Treatment Na?ve Chronic Hepatitis B in Bangladesh: Younger Populations are More Affected; HBeAg-negatives are More Advanced. The Saudi Journal of Gastroenterology 2008 14(1): 15-9
  29. Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and HBsAgseroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013; 58: 923?31.
  30. T?re-?zdemir F, Duman D, Ertem D, Avşar E, Eren F, ?zdoğan O, Kalaycı C, Aslan N, Bozdayı AM, T?z?n N. Determination of hepatitis B genotips in patients with chronic hepatitis B virus infection in Turkey. Turk. J. Gastroeneterol 2005; 16: 183-87.
  31. Bozdayı M, Bozkaya H, T?rkyılmaz H, et al. Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels. J. Clin. Virol. 2001; 21: 91-101.
  32. Yal?ın K, Değertekin H, Bahcecioğlu IH et al. Hepatitis B virus genotype D prevails in patients with persistently elevated or normal ALT levels in Turkey. Infection 2004; 32: 24-29.

[Muammer Bilici, Muhammet EminKutu, Yasin Ozturk and Yucel Ustundag. (2019); THE VALUE OF HBSAG MONITARIZATION IN CHRONIC HEPATITIS B PATIENTS TREATED WITH ORAL ANTIVIRAL THERAPY. Int. J. of Adv. Res. 7 (Jan). 895-900] (ISSN 2320-5407). www.journalijar.com

Muammer Bilici
Bulent Ecevit University

DOI:

Article DOI: 10.21474/IJAR01/8398      
DOI URL: http://dx.doi.org/10.21474/IJAR01/8398

Download Full Paper

Download PDF No. of Downloads: 18 | No. of Views: 52